CareDx
NASDAQ: CDNABrisbane, US · Delaware corporation
Find your way into CareDx
605 people in our graph share verified history with the CareDx team — schools, employers, funds. One of them is your warm intro.
Tom Hulmeunlockedknows Anders Karlsson · together at Harvard Business School (overlapped)
×2knows the team · via Henley Business School
×3knows the team · via Harvard Business School
×4knows the team · via McKinsey & Co
×2knows the team · via Heidelberg University
CareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
Founders & leadership
JY
James YeeExecutive
AK
Anders KarlssoninExecutiveAnders Karlsson held senior leadership roles in pharma, biotech, and medtech, including CEO of Allenex AB (listed on NASDAQ Stockholm) and Managing Director/Country Head for Novartis Norway. He is an executive officer at CareDx, managing international operations for the transplant diagnostics company.
TW
Todd WhitsoninExecutive
PM
Peter MaaginExecutiveHe has background in pharmaceuticals and diagnostics across multiple geographies, with experience in general management, commercial operations, and product innovation.
JS
John SninskyinExecutive
CC
Charles ConstantiinExecutiveCharles Constanti served as CFO at multiple technology companies including Swimlane, BlastWave, CareDx, Procera Networks, and Netopia, managing finance, accounting, and operations teams across public and private organizations. He began his career as an auditor at PwC and has led financial planning, capital raising, and operational scaling at venture-backed and public companies in SaaS and networking sectors.
MN
Mitchell NellesExecutive
MM
Matthew MyerExecutive
JW
John W. HannainPresident and Chief Executive OfficerJohn W. Hanna is President and Chief Executive Officer of CareDx, which develops diagnostic tools and solutions for transplant patients across the pre- and post-transplant continuum. He has led organizations through mergers, turnarounds, and market expansions, with experience in corporate development, product commercialization, and strategic planning.
KK
Keith KennedyinChief Operating Officer and Chief Financial OfficerHe brings over 20 years of executive experience across public accounting, banking, and private equity, including prior roles as Chief Financial Officer and Chief Operating Officer of Veracyte from 2016 to 2021 and Chief Executive Officer of MCG Capital Corporation, alongside positions at GE Capital and Ernst & Young. He holds a B.S. in accounting from Indiana University and an M.B.A. from the College of William & Mary, and is a Chartered Financial Analyst and Certified Public Accountant.
JM
Jessica MenginChief Commercial OfficerShe previously held commercial leadership roles at Veracyte, Genentech, Myovant Sciences, and DELFI Diagnostics, with expertise spanning oncology, immunology, and molecular diagnostics.
Board
MG
Michael GoldbergBoard director
Reported raises · per SEC filings
Form D private placements$22.2M disclosed across 1 round · 2016
▶$22.2MraisedJun 2016 · 42 investors · BiotechnologyRule 506(b)
▶$22.2MraisedJun 2016 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HagstromDirector
- Ralph SnydermanDirector
- James YeeExecutive Officer
- Anders KarlssonExecutive Officer
- Todd WhitsonExecutive Officer
- Michael GoldbergDirector
- Peter MaagExecutive Officer, Director
- John SninskyExecutive Officer
- George BickerstaffDirector
- Charles ConstantiExecutive Officer
- Mitchell NellesExecutive Officer
- Matthew MyerExecutive Officer
- Fred CohenDirector
- Offering amount
- $36.8M
- Amount sold
- $22.2M
- Sales commissions
- $1.1M
- Finders' fees
- $11.7K
- Placement agents
- M.M. Dillon & Co. Group, CIM Securities, LLC, Leerink Partners LLC
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapKidney249 shared keywordsThe National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services. The organization serves patients with kidney disease and at-risk communities.
UPMC170 shared keywordsUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Companies competing with CareDx for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA? - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does CareDx do?
- CareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
- How much funding has CareDx raised?
- CareDx has disclosed $22.2M raised across 1 round.
- Where is CareDx headquartered?
- CareDx is headquartered in Brisbane, US.